Transmissive spongiform encephalopathies (TSE) are neurodegenerative diseases characterized by depositions of abnormally folded prion protein (PrP(TSE)) in brain. PrP(TSE) is at present the only specific biochemical marker of human and animal TSE. As deposits of PrP(TSE) remain in the body for long periods, there is substantial chance of them being nonenzymatically modified by glycation. The detection of glycated PrP(TSE) may have potential to serve as a diagnostic marker. Monoclonal antibodies specific for carboxymethyl lysine/arginine-modified prion protein were prepared. Recombinant human prion protein (rhPrP) was bacterially expressed and purified by affinity chromatography. rhPrP was modified by glyoxylic acid that introduces carboxymethyl groups on lysine and arginine residues present within the molecule of the protein. Modified rhPrP (rhPrP-CML) was used for immunization of 6 mice, and 960 hybridoma cells were prepared. Screening of cell supernatants resulted in the selection of four promising clones. One of them (EM-31) strongly reacts with human and mouse recombinant PrP-CML, and three other clones react also with CML in vitro modified human and mouse brain PrP. Besides possible implication in TSE diagnostics, the antibodies may serve as tolls to advance our knowledge regarding the role of glycation in the prion pathophysiology.

Institute of Immunology and Microbiology 1st Faculty of Medicine Charles University Prague Studnickova 7 Prague 2 Czech Republic

Zobrazit více v PubMed

Ando K., Beppu M., Kikugawa K., Nagai R., Horiuchi S. Membrane proteins of human erythrocytes are modified by advanced glycation end products during aging in the circulation. Biochem. Biophys. Res. Commun. 1999;258:123–27. PubMed

Armitage W. J., Tullo A.B., Ironside J. W. Risk of Creutzfeldt-Jakob disease transmission by ocular surgery and tissue transplantation. Eye (Lond.) 2009;23:1926–30. PubMed

Brown P., Brandel J. P., Preece M., Sato T. latrogenic Creutzfeldt-Jakob disease: The waning of an era. Neurology. 2006;67:389–93. PubMed

Brownlee M., Vlassara H., Cerami A. Non-enzymatic glycosylation and the pathogenesis of diabetic complications. Ann. Intern. Med. 1984;101:527–37. PubMed

Choi Y. G., Kim J. I., Jeon Y. C., Park S. J., Choi E. K., Rubenstein R., Kascsak R. J., Carp R. I., Kim Y. S. Nonenzymatic glycation at the N terminus of pathogenic prion protein in transmissible spongiform encephalopathies. J. Biol. Chem. 2004;279:30402–9. PubMed

Grassi J., Maillet S., Simon S., Morel N. Progress and limits of TSE diagnostic tools. Vet. Res. 2008;39:33. PubMed

Holada K., Simak J., Brown P., Vostal J. G. Divergent expression of cellular prion protein on blood cells of human and nonhuman primates. Transfusion. 2007;47:2223–32. PubMed

Miranda H. V., Outeiro T. F. The sour side of neurodegenerative disorders: The effects of protein glycation. J. Pathol. 2009;221:13–25. PubMed

Monnier V. M., Cerami A. Nonenzymatic browning in vivo: Possible process for aging of long-lived proteins. Science. 1981;211:491–93. PubMed

Panigaj M., Brouckova A., Glierova H., Dvorakova E., Simak J., Vostal J. G., Holada K. Underrated expression of cellular prion protein on human red blood cells. Transfusion. 2011;51:1012–21. PubMed

Pavlicek A., Bednarova L., Holada K. Production, purification and oxidative folding of the mouse recombinant prion protein. Folia Microbio!. 2007;52:391–97. PubMed

Reddy S., Bichler J., Wells-Knecht K. J., Thorpe S. R., Baynes J. W. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry. 1995;34:10872–78. PubMed

Sasaki N., Takeuchi M., Chowei H., Kikuchi S., Hayashi Y., Nakano N., Ikeda H., Yamagishi S., Kitamoto T., Saito T., Makita Z. Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci. Lett. 2002;326:117–20. PubMed